nach oben

Erschienen in:

01.05.2015 | Review

Concerns regarding approval and sale of FDCs in India

Erschienen in: Reactions Weekly | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

The concerns raised in a 2012 report by an Indian parliamentary committee (‘the 59th Report’) appear to be valid regarding the proliferation of fixed dose combination (FDC) products in India − some of which have not been approved by the Central Drugs Standard Control Organization (CDSCO) or by regulators in the UK or US, according to the results of an ‘ecologic study’ conducted by researchers from the UK and India. …

McGettigan P, et al. Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs. PLoS Medicine : [28 pages], 12 May 2015. Available from: URL: http://doi.org/10.1371/journal.pmed.1001826

Titel: Concerns regarding approval and sale of FDCs in India
Publikationsdatum: 01.05.2015
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2015
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-015-1774-4

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Concerns regarding approval and sale of FDCs in India

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Deflazacort/prednisone

Corticosteroids

Peginterferon/ribavirin

Canagliflozin: ISMP assesses benefits and risks post-launch

Corticotropin

Asenapine/lithium